The FDA has granted new designations for investigational #RareDisease gene therapies that are part of the #AMP #BGTC program, managed by Foundation for the National Institutes of Health. These designations provide incentives for companies to further develop and market them and bring treatments to patients faster! Learn more about this exciting news: https://go.nih.gov/9C2zdBo #RareDiseases
National Center for Advancing Translational Sciences (NCATS)
Research
Rockville, Maryland 18,614 followers
About us
The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, conducts and supports research on the science and operation of translation to allow more treatments to get to more patients more quickly. The center focuses on what is common across diseases and the translational process by studying translation on a system-wide level as a scientific and operational problem. Working in partnership with the public and private sectors, NCATS strives to develop innovations to reduce, remove or bypass costly and time-consuming bottlenecks in the translational research pipeline; demonstrate their usefulness; and disseminate the resulting data to the broader scientific community. For more information, visit https://ncats.nih.gov. engagement ≠ endorsement
- Website
-
https://ncats.nih.gov
External link for National Center for Advancing Translational Sciences (NCATS)
- Industry
- Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Government Agency
- Founded
- 2011
Locations
-
Primary
9609 Medical Center Dr
Rockville, Maryland 20850, US
Employees at National Center for Advancing Translational Sciences (NCATS)
-
Thomas C. Radman
Program Director at National Center for Advancing Translational Sciences
-
Rafat Sarosh
AI for Enterprise, Relentless Optimists and Practical Builder.
-
Audie Atienza
Senior Program Officer, NCATS/NIH [VIEWS ARE MY OWN]; Founder, The XA Project [501(c)(3) non-profit]
-
Dmitry Krantsberg
Updates
-
A recent NCATS-supported randomized controlled trial found when patients self-administer a low dose of nitrous oxide — also known as laughing gas — during invasive urinary-tract tests, they may reduce anxiety and pain without affecting test results. Read more: https://lnkd.in/druvVWzG #CTSAProgram Harvard Catalyst | The Harvard Clinical and Translational Science Center
-
In a recent study, NCATS researchers found a possible new treatment option for depression and pain. The findings from an early-stage clinical trial showed the new ketamine metabolite was safe in people and did not cause the drug’s negative side effects. Read how we helped design the new treatment that could act as an antidepressant without ketamine’s sedation or dissociative symptoms. https://go.nih.gov/HsuGSzN
-
NCATS Small Businesses: The Diversity Supplement is BACK! 🎉 Calling all NCATS SBIR/STTR awardees! We're excited to announce that the opportunity to apply for administrative supplements to enhance diversity in your research teams has been reissued! Here's how the Diversity Supplement can make a difference: ➡️ Recruit & mentor students, postdocs, and eligible investigators from underrepresented groups ➡️ Support the inclusion of researchers with disabilities by providing funds to accommodate their needs and ensure continued participation in vital research projects ➡️ Build a more inclusive & innovative research environment Learn more about this funding opportunity (PA-23-255) & eligibility requirements here: Small Business Resources: https://go.nih.gov/OujjbuE Don't miss out! Applications are accepted on a rolling basis. Share this post and help us champion diversity in translational research!
-
NCATS, the National Human Genome Research Institute (NHGRI), Simon Fraser University and Roche created a screening approach that can sift thousands of drug compounds in a predictive, disease-relevant and cell-based system. This design rapidly revealed drugs that can rescue and help restore defective versions of an enzyme that is a contributor to Gaucher disease — a #RareDisease — and #ParkinsonsDisease. Learn how this innovative approach is speeding up new therapies for these diseases: https://go.nih.gov/gG5QYdS
-
NCATS Office of Translational Medicine Director Josh Fessel, M.D., Ph.D., spoke at the Chronic Disease Day hosted by Good Days on Capitol Hill. Dr. Fessel noted some chronic diseases are common; many others are rare — highlighting the need to support the treatment and prevention of #RareDiseases as well as common diseases. Read more on Dr. Fessel: https://go.nih.gov/UAH0WVI Read more on Chronic Disease Day: https://lnkd.in/ewYicN5j
In July, NIAMS Director Lindsey Criswell spoke at a congressional briefing on chronic disease management and prevention. Taking place in the Rayburn House Office Building, the event also featured speakers from NIH’s National Center for Advancing Translational Sciences (NCATS), the CDC’s National Center for Chronic Disease Prevention and Health Promotion, and more. The NIH Record has the full story: https://lnkd.in/ewYicN5j
-
In one week, our Assay Guidance Manual Program is hosting a free 𝐼𝑛 𝑠𝑖𝑙𝑖𝑐𝑜 Drug Discovery Virtual Workshop. This event will cover concepts and best practices for integrating #ArtificialIntelligence and #MachineLearning into #DrugDiscovery pipelines. If you didn't get a chance to register, tune into the two-day event using the links below. Day 1 — Wednesday, Oct. 23, 2024, 11:00 a.m.–5:15 p.m.: https://lnkd.in/ekb65Bds Day 2 — Thursday, Oct. 24, 2024, 11:00 a.m.–5:15 p.m.: https://lnkd.in/ePn-APeG View the agenda featuring newly-minted Nobel laureate David Baker, Ph.D.: https://lnkd.in/ecrUW9eB
-
🚨 Last Chance for Game-Changing Research Funding! 🚨 The clock is ticking! ⏳ Don't miss your chance to secure NIH SBIR/STTR funding for your groundbreaking research. The deadline to apply is Oct. 18. This is your opportunity to: • Revolutionize batch evaporation with your innovative benchtop device. • Advance personalized medicine by developing liver and brain organoids from iPS cells. Don't wait! Submit your application today: https://lnkd.in/ezcaVEpj #NCATSsbir #SBIRSTTR #researchfunding #innovation #biotech
-
If you’re attending SACNAS #2024NDiSTEM, hear NCATS Intramural Translational Training Director Dr. Belen Hurle speak! ➡️Nov. 1 at 5:15 p.m. EDT for Training at the NIH: Success Stories and Advice from Hispanic Leaders ➡️Nov. 2 at 1:30 p.m. EDT for Found in Translation: Diversity and Inclusion in Translational Research Learn more about Dr. Hurle: https://go.nih.gov/SjjJ5HM #TrueDiversity #HispanicHeritageMonth
-
Thank you to all participants! The answer is: True By advancing #TranslationalScience, we can make research more efficient and impactful, resulting in more treatments for all people more quickly. To learn more, explore the NCATS Strategic Plan for 2025–2030: https://go.nih.gov/8ksiTZ9
This content isn’t available here
Access this content and more in the LinkedIn app